Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Terminal sialic acid residues are nine-carbon acidic monosaccharides typically found at the outermost positions of glycan chains on the surface of host cell glycoproteins and glycolipids. These residues are essential for various biological processes, including cell-cell recognition, signal transduction, and the regulation of the immune system by acting as self markers that prevent autoimmune responses (Varki, 2008). However, they are also frequently utilized as attachment receptors by a wide range of pathogens, most notably the influenza virus, which uses its hemagglutinin protein to bind to specific sialic acid linkages (Schauer, 2009). In cancer, the upregulation of terminal sialic acids, or hypersialylation, facilitates tumor progression by promoting metastasis and allowing the tumor to evade immune detection through interactions with Siglec receptors on leukocytes (Bull et al., 2014). Therapeutic approaches include the use of inhaled recombinant sialidases, such as DAS181, which enzymatically remove these residues to prevent viral entry, as well as neuraminidase inhibitors that block the viral enzyme from cleaving these residues during the budding of new virions (Moss et al., 2012).
Enzymatic cleavage of terminal sialic acid residues from host cell surfaces to prevent viral attachment; inhibition of viral neuraminidase to prevent the cleavage of sialic acid and release of viral progeny.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Terminal sialic acid residues (Sia).